Auvelity: New Oral Fast Acting FDA Approved Antidepressant
On Aug 19, 2022 Axsome Therapeutics announced the FDA Approval of Auvelity, as the first and Only Oral NMDA Receptor Antagonist for the treatment of Major Depressive Disorder in adults.
We have summarized this FDA-approved medication in the following
Psychiatry Education Forum Academy Updates:
(CORRECTION: In the mechanism section, it is SIGMA RECEPTOR AGONISM & NOT ANTAGONISM)
Dr. Harvinder Singh has discussed Auvelity in the following sections:
FDA-APPROVED INDICATION:
LIKELY MECHANISM OF ACTION?
HOW TO DOSE AUVELITY?
USE IN SPECIAL POPULATIONS
COMMON ADVERSE REACTIONS
CONTRAINDICATIONS
IMPORTANT DRUG INTERACTIONS
IMPORTANT CLINICAL FACTS
CLINICAL TRIALS SUPPORTING RAPID ONSET OF ACTION
REFERENCES:
- AUVELITY package insert. (pdf)
- Am J Psychiatry. 2022 Jul;179(7):490-499. PMID: 35582785.
- J Clin Psychiatry. 2022 May 30;83(4):21m14345. PMID: 35649167.
- Pharmacopsychiatry. 2022 Jul;55(4):193-202. PMID: 35045580.
- CNS Drugs. 2021 May;35(5):527-543. PMID: 33904154.
- Announcement
